© 2025 MJH Life Sciences™ and Patient Care Online. All rights reserved.
Grace Halsey
Articles
Investigational Nonopioid Cebranopadol Meets Primary Endpoint in Pivotal Phase 3 ALLEVIATE-1 Clinical Trial
January 29, 2025
Cebranopadol developer Tris Pharma expects to submit an NDA to the FDA for the dual-NMR agonist to treat moderate-to-severe acute pain later this year.
Tris Pharma's Cebranopadol Shows Low Potential for Misuse in Intranasal Human Abuse Potential Study
January 29, 2025
The novel dual NMR agonist was scored significantly less "likable" when crushed and taken intranasally compared with oxycodone, the company reported.
Neurocrine Biosciences Launches Phase 3 Registration Program for Osavampator in Major Depressive Disorder
January 28, 2025
The investigational and potentially first-in-class therapy may enhance AMPA receptor sensitivity to glutamate, enhancing neuronal transmission.
Patient Selection for Lecanemab to Treat Early Alzheimer Dementia: Details with R Scott Turner, PhD, MD
January 28, 2025
Dr Turner reviews the profile of the individual who is most likely to benefit from lecanemab therapy.
Enobosarm Preserves Lean Body Mass in Older Adults Treated with Semaglutide for Weight Reduction: Topline Phase 2b Data
January 27, 2025
In preliminary findings of the phase 2b QUALITY trial, 32% of weight loss in the semaglutide group was from lean mass reduction vs 9.4% in the combined semagutide/enobosarm group.
Tapinarof 1% Cream Significantly Improves Patient Reported Outcomes, Including Family QoL, in Atopic Dermatitis
January 27, 2025
Tapinarof 1% cream when used as topical monotherapy led to statistically significant and sustained improvements in QoL, sleep, and other PROs across age groups.
Lecanemab Monthly IV Maintenance Dosing: Research Highlights with R Scott Turner, PhD, MD
January 27, 2025
Georgetown University memory disorders expert R Scott Turner, PhD, MD, reviews the science behind approval of lecanemab for monthly maintenance dosing of lecanemab.
FDA Approves Monthly IV Maintenance Dosing of Lecanemab for Adults with Early Alzheimer Dementia: A First in Long-Term Disease Management
January 27, 2025
Once every four weeks maintenance dosing of lecanemab may be easier for patients and care partners to continue treatment.
3 Studies on Major Depressive Disorder: Physical, Pharmacologic, and Neuromodulatory Interventions Explored
January 24, 2025
Findings on the efficacy of treatments for MDD include the favorable effects of exercise, of CBT, and the robust outcomes of ECT among neuromodulatory modalities.